Vistagen Completes Phase 3 PALISADE-3 Trial for Social Anxiety Disorder
Vistagen Completes Phase 3 PALISADE-3 Trial Evaluating Fasedienol for Acute Treatment of Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company advancing neuroscience through innovative nose-to-brain therapeutics, announced…
Kyowa Kirin International Names Julie Dehaene-Puype as New Regional President
Kyowa Kirin International Appoints Julie Dehaene-Puype as President, Ushering in a New Era of Leadership and Growth Kyowa Kirin International (“KKI”), a regional group company of Kyowa Kirin Co., Ltd.…
Lupin Digital Health Unveils VITALYFE™, an AI-Powered Platform to Combat India’s Growing Cardiometabolic Crisis
Lupin Digital Health Launches VITALYFE™, an AI-Powered Platform to Boost Heart Health for India’s Workforce Lupin Digital Health, India’s leading cardiac digital-therapeutics company, today announced the launch of VITALYFE™, an…
Nearly One-Third of Life Sciences Professionals Considering Careers Abroad, BioSpace Survey Finds
Almost 1/3 Eyeing Job Options Outside US, BioSpace Finds Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to a BioSpace LinkedIn poll. Career coaches…
FDA Rejects Regeneron’s Eylea HD Citing Manufacturing Deficiencies.
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues. Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital…
FDA Faces Operational Strain Amid Government Shutdown, Causing Delays for Biopharma Companies
FDA Struggles to Keep Lights On Amid Shutdown as Biopharmas Begin To See Delays While the FDA continues to put out guidance documents and approve drugs, some companies are already…
5 Small and Mid-Cap Pharma Companies Ripe for M&A Deals
5 SMID-Cap Pharmas Poised for M&A Action Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to…
A Disrupted Flu Season Tests Biopharma’s Resilience and Redefines Vaccine Strategy
Opinion: An Unpredictable Flu Season Brings Both Challenges and Opportunities for Biopharm vaccine The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, prevention and…
Pharma Companies Hope FDA PreCheck Program Will Reduce Facility-Related Drug Rejections
Pharmas Hope FDA PreCheck Can Help Avoid Facility-Related Drug Rejections Executives from Eli Lilly, Merck and other companies foresee the FDA’s new onshoring proposal being anything from a bureaucratic waste…
Roche Announces Positive Phase III Results for Gazyva in Idiopathic Nephrotic Syndrome
Study shows Roche Gazyva/Gazyvaro significantly improves outcomes in pediatric and young adult patients with idiopathic nephrotic syndrome. Roche Announces Positive Phase III Results for Gazyva in Idiopathic Nephrotic Syndromeannounced today…
GSK and Empirico Partner on First-in-Class Oligonucleotide for Respiratory Diseases
Gsk Partnership to advance first-in-class siRNA therapy for COPD and other respiratory diseases. GSK plc and Empirico Inc. (Empirico), a clinical-stage biotechnology company with leading capabilities in human genetics-driven target…
Health Canada Approves LEQEMBI® (lecanemab) for the Treatment of Early-Stage Alzheimer’s Disease.
Health Canada Grants Authorization for LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of…